Takeda Pharmaceutical (TAK) Receivables Refunds (2018 - 2025)
Takeda Pharmaceutical (TAK) has 8 years of Receivables Refunds data on record, last reported at $103.5 million in Q1 2025.
- For Q1 2025, Receivables Refunds fell 47.49% year-over-year to $103.5 million; the TTM value through Mar 2025 reached $103.5 million, down 47.49%, while the annual FY2025 figure was $103.7 million, 48.82% down from the prior year.
- Receivables Refunds reached $103.5 million in Q1 2025 per TAK's latest filing, down from $197.1 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $279.9 million in Q1 2021 and bottomed at $103.5 million in Q1 2025.
- Average Receivables Refunds over 5 years is $212.6 million, with a median of $238.6 million recorded in 2022.
- Peak YoY movement for Receivables Refunds: grew 9.15% in 2021, then tumbled 47.49% in 2025.
- A 5-year view of Receivables Refunds shows it stood at $279.9 million in 2021, then decreased by 14.73% to $238.6 million in 2022, then grew by 2.21% to $243.9 million in 2023, then decreased by 19.2% to $197.1 million in 2024, then crashed by 47.49% to $103.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables Refunds were $103.5 million in Q1 2025, $197.1 million in Q1 2024, and $243.9 million in Q1 2023.